Genitourinary Cancers

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.

Dr Shawnta Anakwah presents the patient profile of a 72-year-old man with advanced renal cell carcinoma presenting with hematuria.

Pedro Barata, MD, MSc, provides a brief overview of ongoing trials in the neoadjuvant setting in patients with RCC.

Dr Bilen reviews some ongoing trials looking into monotherapy and combination therapies in the adjuvant setting in RCC.

Key opinion leaders discuss the common adverse events seen with IO/IO combination regimens and how to treat patients with brain metastases.

A review of the first-line IO/IO combination regimens available for advanced RCC.

David Braun, MD, touches on how the choice of adjuvant therapy can impact subsequent treatment selection in advanced RCC.

Dr Zhang discusses recently approved adjuvant systemic therapy for patients with RCC who have a high risk of recurrence after nephrectomy.

The IL-2 variant immunotherapy nemvaleukin alfa elicited responses and demonstrated safety as a single agent and in combination with pembrolizumab in patients with advanced renal cell carcinoma.

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Mehmet A. Bilen, MD, explains how triplet regiments might impact treatment selection for first line and beyond.

The panel elaborates on novel agents and combination treatments that are currently being evaluated for the first-line setting in advanced RCC.

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Shawnta Anakwah, MD, presents the patient profile of a 48-year-old man with advanced renal cell carcinoma presenting with a right renal mass.

Drs Anakwah and Basu share their thoughts on the duration of treatment with I/O–TKI regimens and what treatment options are available for patients at progression of renal cell carcinoma.

Experts review adverse events commonly observed with IO/TKI combination regimens in patients with RCC and how these are managed in clinical practice.

Oncologists discuss which patients with advanced RCC might be most suitable for treatment with lenvatinib + pembrolizumab and the appropriate dosing strategies for this regimen.

Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.

Nektar Therapeutics and Bristol Myers Squibb have announced the decision to end the global clinical development program for the combination of bempegaldesleukin and nivolumab based on findings from preplanned analyses of 2 late-stage clinical trials.

Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.